TREMFYA was studied up to 12 weeks in adult subjects with moderately to severely active ulcerative colitis in a randomized, double …
FDA Approves Inflammex: Novel Biologic for Ulcerative Colitis
Apr 19, 2026 · Inflammex is approved for patients with moderate to severe ulcerative colitis. Eligibility criteria typically include …
FDA Approves Guselkumab for Treatment of Ulcerative Colitis
Sep 12, 2024 · Tremfya (guselkumab) receives US FDA approval for adults with moderately to severely active ulcerative colitis, …
New Ulcerative Colitis Medications: FDA-Approved Drugs Since 2021
Feb 17, 2026 · Mirikizumab (Omvoh) is a medication approved by the FDA in October 2023 to treat moderate to severe ulcerative …
Tremfya Approved for Moderate to Severe Ulcerative Colitis
Sep 23, 2024 · Tremfya® (guselkumab) receives US FDA approval for adults with moderately to severely active ulcerative colitis, …
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with ...
Sep 11, 2024 · Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that causes inflammation in the digestive tract …
Frontiers | Advancing therapeutic frontiers: a pipeline of novel drugs ...
Jan 30, 2026 · Figure 1 presents a comprehensive timeline of all FDA-approved therapies for ulcerative colitis from 2006 to 2024, …
U.S. Food and Drug Administration (FDA) Approves Updated Indication ...
Oct 13, 2025 · This label update gives healthcare providers the option to prescribe RINVOQ for patients with moderately to severely …
Living guideline for pharmacological management of moderate-to-severe ...
Nov 19, 2024 · As part of the AGA living guideline development process, the guideline panel members reviewed new ulcerative …
Ulcerative Colitis Clinical Trials 2026: FDA-Approved Biologics, New …
Mar 15, 2026 · Mirikizumab (Omvoh, Eli Lilly) received FDA approval for moderately to severely active UC in June 2023. The …